All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @cbronsonmd on TikTok · 59s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @cbronsonmd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I've never seen an obese middle age male put simultaneously on
  2. 0:04semaglutide, terzapatide plus TRT, who's a year later, assuming they
  3. 0:10stuck to it and assuming their lifestyle was reasonable and they did
  4. 0:14resistance training.
  5. 0:16I don't even take patients who don't do resistance training, by the way,
  6. 0:19that's one of our screening thing.
  7. 0:20If you don't lift weights, I don't even fuck you at my clinic period.
  8. 0:24But that being said, so the guys that get put on that combination of drugs
  9. 0:29their body composition changes a year later, I get profound because the
  10. 0:34testosterone, even in the worst case, preserves their muscle mass while
  11. 0:39they lose fat.
  12. 0:40I cringe whenever I see men come in with body composition scans of six months
  13. 0:47after starting, or zemper.
  14. 0:49And they're like, yeah, I've lost 40 pounds.
  15. 0:52I'm like, yeah, but your percent body fat's the same.
  16. 0:54You've lost a significant amount of muscle.
  17. 0:57That's not going to help your metabolism.

@cbronsonmd's semaglutide plus TRT claims, fact-checked

cbronsonMD

TikTok creator

227.0K viewsWatch on TikTok

Quick answer

The creator is describing a clinical protocol combining GLP-1 receptor agonists with testosterone replacement therapy and mandatory resistance training for obese middle-aged men with presumed hypogonadism or hormone insufficiency. His central concern, that GLP-1 therapy alone causes significant lean mass loss that blunts metabolic benefit, is supported by available evidence on semaglutide and muscle composition. The triple-combination protocol has biological plausibility but lacks randomized controlled trial data specifically evaluating it as a combined intervention.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @cbronsonmd's semaglutide plus TRT claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@cbronsonmd's semaglutide plus TRT claims, fact-checked" from cbronsonMD. We read the clip as a TRT social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is describing a clinical protocol combining GLP-1 receptor agonists with testosterone replacement therapy and mandatory resistance training for obese middle-aged men with presumed hypogonadism or hormone insufficiency.

The reason this review is not generic is the source wording and the canonical claim label "trt semaglutide ozempic trt resistance training testoster." In this clip, the useful excerpt is: "I've never seen an obese middle age male put simultaneously on semaglutide, terzapatide plus TRT, who's a year later, assuming they stuck to it and assuming their lifestyle was reasonable and they did resistance training." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Testosterone replacement therapy has evidence for reducing lean mass loss during caloric deficit in older men, per Srinivas-Shankar et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is describing a clinical protocol combining GLP-1 receptor agonists with testosterone replacement therapy and mandatory resistance training for obese middle-aged men with presumed hypogonadism or hormone insufficiency.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is describing a clinical protocol combining GLP-1 receptor agonists with testosterone replacement therapy and mandatory resistance training for obese middle-aged men with presumed hypogonadism or hormone insufficiency. His central concern, that GLP-1 therapy alone causes significant lean mass loss that blunts metabolic benefit, is supported by available evidence on semaglutide and muscle composition. The triple-combination protocol has biological plausibility but lacks randomized controlled trial data specifically evaluating it as a combined intervention.
  • Studies from the STEP 1 trial (Wilding et al., 2021, NEJM) show roughly 25-40% of semaglutide-driven weight loss comes from lean mass, not fat, which is a real and underreported problem.
  • Testosterone replacement therapy has evidence for reducing lean mass loss during caloric deficit in older men, per Srinivas-Shankar et al. (2010, JCEM), but has not been tested in a controlled trial specifically combined with GLP-1 therapy.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Studies from the STEP 1 trial (Wilding et al., 2021, NEJM) show roughly 25-40% of semaglutide-driven weight loss comes from lean mass, not fat, which is a real and underreported problem.
  • Testosterone replacement therapy has evidence for reducing lean mass loss during caloric deficit in older men, per Srinivas-Shankar et al. (2010, JCEM), but has not been tested in a controlled trial specifically combined with GLP-1 therapy.
  • Resistance training is the single best-supported intervention for preserving muscle during weight loss. Requiring it as part of a GLP-1 or TRT protocol reflects actual evidence, not just preference.
  • Losing weight without protecting lean mass can leave body fat percentage unchanged or worse, reducing metabolic benefit and increasing long-term regain risk.
  • No randomized controlled trial has evaluated the specific combination of GLP-1 agonist plus TRT plus resistance training. The creator's results are observational from his own patients, which introduces selection and confirmation bias.
  • TRT carries its own risk profile, including erythrocytosis, cardiovascular considerations, and fertility suppression. This video does not address monitoring requirements, which are essential to safe use.
  • Anyone considering this protocol based on social media content is missing the lab monitoring and clinical oversight that makes it manageable in a supervised setting.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @cbronsonmd actually say?

The claim is this: middle-aged men who combine GLP-1 agonists like semaglutide or tirzepatide with testosterone replacement therapy and resistance training see "profound" body composition changes after a year. He also argues that men on GLP-1 drugs alone lose significant muscle alongside fat, leaving their body fat percentage essentially unchanged. His clinic, he says, won't even take patients who don't lift weights.

That's actually a more specific and defensible argument than most TikTok doctors make. He's not saying these drugs are magic. He's saying the combination addresses two separate problems: the fat loss mechanism and the muscle preservation mechanism. That distinction matters, and it's worth taking seriously.

Does the science back this up?

Mostly, yes, with some important caveats. The muscle loss concern with GLP-1 agonists is real and well-documented. Studies suggest that roughly 25-40% of weight lost on semaglutide is lean mass, not fat, which is consistent with weight loss by almost any method. Testosterone's role in muscle preservation during caloric deficit is also supported by evidence.

Biolo et al. (1997, American Journal of Physiology) established that testosterone promotes muscle protein synthesis, and more recent work by Srinivas-Shankar et al. (2010, Journal of Clinical Endocrinology and Metabolism) confirmed that testosterone supplementation in older men during caloric stress reduces lean mass loss. Resistance training compounds this effect. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide produces roughly 15% body weight reduction, but did not systematically protect lean mass. Combining TRT with GLP-1 therapy has not been tested in a large randomized controlled trial specifically, so the "profound" transformation claim is clinical anecdote, not controlled evidence.

What did they get wrong (or right)?

He got the core physiology right. Testosterone does preserve muscle during a caloric deficit better than no testosterone. GLP-1 agonists do cause meaningful lean mass loss in the absence of countermeasures. Resistance training is the single best-studied intervention for maintaining muscle during weight loss. These are not controversial statements.

Where he oversells: "profound" body composition changes after a year is observational language from a clinician watching his own patients. That's not nothing, but it's also not a controlled study. Confirmation bias is a real problem when you're the one prescribing the drugs and celebrating the results. His screening requirement for resistance training also means the patients he's comparing are not representative of average GLP-1 users, which limits how broadly you can apply his conclusions.

The body composition scan example he gives, where someone loses 40 pounds but their body fat percentage stays the same, is clinically accurate and genuinely underappreciated. That scenario represents losing roughly equal amounts of fat and muscle, which is a real metabolic problem. He's right to flag it.

What should you actually know?

If you're a man on a GLP-1 agonist and you're not doing resistance training, your muscle mass is at risk. That's not speculation. Deutz et al. (2017, Clinical Nutrition) found that older adults losing weight without resistance exercise lose disproportionate lean mass. Testosterone deficiency amplifies this problem because low testosterone already accelerates muscle breakdown independently of diet.

What's missing from this video is any acknowledgment that TRT is a controlled medical intervention with its own risk profile, including erythrocytosis, cardiovascular considerations, and fertility suppression. The combination of TRT plus GLP-1 therapy in men with obesity has not been studied in a rigorous trial. Anyone seeing this video and thinking they can self-assemble this protocol is missing the clinical monitoring that makes it relatively safe in a supervised setting.

The resistance training requirement his clinic uses is actually sensible harm reduction. It's not standard across TRT practices, but it reflects real evidence that exercise is load-bearing for the outcomes he's describing.

Our bottom line

This video is more grounded than most hormone-optimization content on TikTok. The mechanisms he describes are real. The muscle loss concern with GLP-1 drugs alone is underreported and worth knowing. But "profound" results after a year of a three-part protocol, described by the prescribing physician, is anecdote. The triple combination of semaglutide or tirzepatide plus TRT plus resistance training has not been tested in a randomized controlled trial. The physiology supports the hypothesis. The proof of concept does not yet exist in the literature.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

cbronsonMD · TikTok creator

227.0K views on this video

Semaglutide (Ozempic) + TRT + Resistance training #testosterone #bodybuilding #testosteronereplacement #menshealth #fatloss #TRT

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about studies from the step 1 trial (wilding et al., 2021,?

Studies from the STEP 1 trial (Wilding et al., 2021, NEJM) show roughly 25-40% of semaglutide-driven weight loss comes from lean mass, not fat, which is a real and underreported problem.

What does the video say about testosterone replacement therapy has evidence for reducing lean mass loss?

Testosterone replacement therapy has evidence for reducing lean mass loss during caloric deficit in older men, per Srinivas-Shankar et al. (2010, JCEM), but has not been tested in a controlled trial specifically combined with GLP-1 therapy.

What does the video say about resistance training?

Resistance training is the single best-supported intervention for preserving muscle during weight loss. Requiring it as part of a GLP-1 or TRT protocol reflects actual evidence, not just preference.

What does the video say about losing weight without protecting lean mass can leave body fat?

Losing weight without protecting lean mass can leave body fat percentage unchanged or worse, reducing metabolic benefit and increasing long-term regain risk.

What does the video say about no randomized controlled trial has evaluated the specific combination of?

No randomized controlled trial has evaluated the specific combination of GLP-1 agonist plus TRT plus resistance training. The creator's results are observational from his own patients, which introduces selection and confirmation bias.

What does the video say about trt carries its own risk profile, including erythrocytosis, cardiovascular considerations,?

TRT carries its own risk profile, including erythrocytosis, cardiovascular considerations, and fertility suppression. This video does not address monitoring requirements, which are essential to safe use.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by cbronsonMD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.